Author/Creator: Cui, D - British Library Electronic Legal Deposit Catalogue-Journal Issues and Articles Search Results

Author/Creator Cui, D

1. DOP50 Oral α4β7 integrin inhibitor MORF-057 demonstrates exposure driven biomarker response in non-human primates. (21st January 2022)

Authors:: Wong, J; Lee, D; Mangada, M; Yadav, V; Troast, D; Zhong, C; Hahn, K; Wang, W; Ge, X; Sun, L; Jiang, S; Wang, B; Zhang, J; Yan, L; Nguyen, H; Cui, D; Bursavich, M G; Lippa, B; Rogers, B N; Ray, A S
Journal:: Journal of Crohn's and colitis
Issue:: Volume 16(2022)Supplement 1
Page Start:: i098
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

2. EP1252 Magnetic resonance fingerprinting of cervical carcinoma- a feasibility study. (1st November 2019)

Authors:: Lee, EYP; Perucho, JA; Cui, D; Hui, ESK
Journal:: International journal of gynecological cancer
Issue:: Volume 29(2019)Supplement 4
Page Start:: A629
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

3. FACTORS ASSOCIATED WITH SOCIAL PARTICIPATION AMONG CHINESE MIDDLE-AGED AND OLDER ADULTS POST-STROKE. (11th November 2018)

Authors:: Cai, Y; Cui, D
Journal:: Innovation in aging
Issue:: Volume 2(2018)Supplement 1
Page Start:: 734
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

4. P037 Nonclinical pharmacokinetics and absorption, distribution, metabolism, and excretion properties of MORF-057 support its clinical development as an oral selective α4β7 integrin inhibitor. (27th May 2021)

Authors:: Jones, J; Lee, D; Smukste, I; Cui, D; Bursavich, M G; Troast, D; Zhong, C; Wong, J E; Mangada, M M; Bain, G; Lippa, B; Ray, A S; Rogers, B N
Journal:: Journal of Crohn's and colitis
Issue:: Volume 15(2021)Supplement 1
Page Start:: S149
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

5. P102 A small molecule selective integrin α4β7 inhibitor demonstrates efficacy in a chronic model of Inflammatory Bowel Disease. (30th January 2023)

Authors:: Redhu, N S; Rowe, M; Lee, D; Jain, D; Sang, A; Granata, D; Harrison, B; Cui, D; Bursavich, M; Ray, A S; Lippa, B; Rogers, B N; Wong, J
Journal:: Journal of Crohn's and colitis
Issue:: Volume 17(2023)Supplement 1
Page Start:: i265
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

6. P306 MORF-057, an oral selective α4β7 integrin inhibitor for Inflammatory Bowel Disease, leads to specific target engagement in a single and multiple ascending dose study in healthy subjects. (27th May 2021)

Authors:: Ray, A; Cui, D; Lee, D; Mangada, M M; Jones, J; Bain, G; Traber, P G; Vrishabhendra, L H; Krzeski, P W; Vande Casteele, N; Reardon, M M; Stern, T P; Soo, C L; Nguyen, H; Rogers, B N; Linde, P G
Journal:: Journal of Crohn's and colitis
Issue:: Volume 15(2021)Supplement 1
Page Start:: S333
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

7. Predictors of intestinal pseudo-obstruction in systemic lupus erythematosus complicated by digestive manifestations: data from a Southern China lupus cohort. (March 2016)

Authors:: Huang, Q; Lai, W; Yuan, C; Shen, S; Cui, D; Zhao, J; Lin, J; Ren, H; Yang, M
Journal:: Lupus
Issue:: Volume 25:Number 3(2016)
Page Start:: 248
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗